Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

The big question for Lilly is whether the data are strong enough to fend off the challenge from Novo Nordisk’s once-weekly GLP-1 agonist Ozempic ... disease or kidney disease as well as earlier ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity, but is coming under competitive pressure ...

Taking the drug made one writer feel so sick she quit and focused on healthy habits instead of her body size. Turns out, 65% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...